☆ 4.2 Article

Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab vs csDMARD therapy alone: an open-label, randomized, parallel-group study

ARTHRITIS RESEARCH & THERAPY (2022)

Related references

Note: Only part of the references are listed.

Article Multidisciplinary Sciences

Analysis of bone erosions in rheumatoid arthritis using HR-pQCT: Development of a measurement algorithm and assessment of longitudinal changes

Kazuteru Shiraishi et al.

Summary: The purpose of this study was to establish an algorithm for measuring bone erosions at metacarpophalangeal (MCP) joints using high-resolution peripheral quantitative computed tomography (HR-pQCT), and to assess the precision and longitudinal changes in bone erosions among patients with rheumatoid arthritis (RA). The algorithm developed showed good reproducibility and both progression and repair of bone erosions were observed in RA patients even after 12 months of treatment.

PLOS ONE (2022)

Add to Collection

Article Rheumatology

Impact of denosumab discontinuation on changes in bone mineral density and bone erosion in rheumatoid arthritis patients

Sakae Tanaka et al.

Summary: This study investigated changes in bone mineral density (BMD) and erosion after discontinuation of denosumab in rheumatoid arthritis (RA) patients without osteoporosis. The results showed that the percentage change in lumbar spine BMD returned to baseline levels after discontinuation. Bone erosion scores did not significantly differ between the on-treatment period and after discontinuation, but there was a numerical increase postdiscontinuation. The progression in bone erosion score was significantly reduced in patients whose disease activity was in remission.

MODERN RHEUMATOLOGY (2022)

Add to Collection

Article Rheumatology

Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies

Tsutomu Takeuchi et al.

Summary: New bone erosion predictors in rheumatoid arthritis patients treated with conventional synthetic disease-modifying antirheumatic drugs include seropositivity, elevated inflammatory markers, and baseline erosion score greater than or equal to 3.

MODERN RHEUMATOLOGY (2021)

Add to Collection

Review Physiology

The Effect of Inflammation on Bone

Scott Epsley et al.

Summary: Bone remodeling is a continual process involving osteoblasts and osteoclasts, where inflammation plays a crucial role in skewing the process towards resorption. Inflammatory mediators interact with bone cells to alter the expression of regulatory factors, leading to various bone-related pathologies. Further research is needed to advance early detection and treatments for bone diseases influenced by inflammation.

FRONTIERS IN PHYSIOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Systemic Bone Density at Disease Onset Is Associated With Joint Erosion Progression in Early Naive to Treatment Rheumatoid Arthritis: A Prospective 12-Month Follow-Up Open-Label Study

Dario Bruno et al.

Summary: The study revealed that bone erosions in rheumatoid arthritis patients are closely associated with systemic bone loss, with early osteoporotic patients being more prone to erosions. Disease activity score and osteopenia/osteoporosis status were identified as independent factors of erosiveness.

FRONTIERS IN MEDICINE (2021)

Add to Collection

Article Rheumatology

Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial

Ho So et al.

Summary: Denosumab showed greater efficacy than placebo in erosion repair in patients with rheumatoid arthritis after 24 months, as seen on HR-pQCT scans. A significant proportion of patients in the denosumab group experienced erosion healing, while no differences in erosion parameters were observed at 12 months.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

Effects of Denosumab in Japanese Patients With Rheumatoid Arthritis Treated With Conventional Antirheumatic Drugs: 36-month Extension of a Phase III Study

Yoshiya Tanaka et al.

Summary: The study evaluated the safety and efficacy of long-term denosumab treatment for patients with rheumatoid arthritis, showing that it effectively inhibits the progression of joint destruction. Higher dosing frequency may be needed in the early treatment stages for optimal results.

JOURNAL OF RHEUMATOLOGY (2021)

Add to Collection

Review Medicine, General & Internal

High-Resolution Peripheral Quantitative Computed Tomography for Bone Evaluation in Inflammatory Rheumatic Disease

Rasmus Klose-Jensen et al.

FRONTIERS IN MEDICINE (2020)

Add to Collection

Review Immunology

Rheumatoid arthritis

Yoshiya Tanaka

INFLAMMATION AND REGENERATION (2020)

Add to Collection

Article Rheumatology

Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial

Tsutomu Takeuchi et al.

ANNALS OF THE RHEUMATIC DISEASES (2019)

Add to Collection

Article Medicine, Research & Experimental

Comparative study of the inhibitory effect on bone erosion progression with denosumab treatment and conventional treatment in rheumatoid arthritis patients: study protocol for an open-label randomized controlled trial by HR-pQCT

Naoki Iwamoto et al.

TRIALS (2019)

Add to Collection

Review Medicine, General & Internal

Rheumatoid Arthritis: A Brief Overview of the Treatment

Jacqueline Bullock et al.

MEDICAL PRINCIPLES AND PRACTICE (2018)

Add to Collection

Article Rheumatology

Smoking, body mass index, disease activity, and the risk of rapid radiographic progression in patients with early rheumatoid arthritis

Emil Rydell et al.

ARTHRITIS RESEARCH & THERAPY (2018)

Add to Collection

Article Rheumatology

Comparison of the efficacy of denosumab and bisphosphonates for treating secondary osteoporosis in patients with rheumatoid arthritis

Hayato Kinoshita et al.

MODERN RHEUMATOLOGY (2017)

Add to Collection

Article Rheumatology

Repair of Bone Erosion in Rheumatoid Arthritis by Denosumab: A High-Resolution Peripheral Quantitative Computed Tomography Study

Jiang Yue et al.

ARTHRITIS CARE & RESEARCH (2017)

Add to Collection

Article Rheumatology

Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial

Tsutomu Takeuchi et al.

ANNALS OF THE RHEUMATIC DISEASES (2016)

Add to Collection

Review Biochemistry & Molecular Biology

Denosumab for the treatment of osteoporosis

Sarah Zaheer et al.

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2015)

Add to Collection

Article Rheumatology

2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

Daniel Aletaha et al.

ANNALS OF THE RHEUMATIC DISEASES (2010)

Add to Collection

Article Rheumatology

Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis

M. Gueler-Yueksel et al.

ANNALS OF THE RHEUMATIC DISEASES (2009)

Add to Collection

Article Endocrinology & Metabolism

Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL

Paul J. Kostenuik et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2009)

Add to Collection

Article Rheumatology

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis

Stanley B. Cohen et al.

ARTHRITIS AND RHEUMATISM (2008)

Add to Collection

Article Rheumatology

Hand bone loss as an outcome measure in established rheumatoid arthritis: 2-year observational study comparing cortical and total bone loss

Mari Hoff et al.

ARTHRITIS RESEARCH & THERAPY (2007)

Add to Collection

Article Rheumatology

Hand bone densitometry in rheumatoid arthritis, a five year longitudinal study: an outcome measure and a prognostic marker

AA Deodhar et al.

ANNALS OF THE RHEUMATIC DISEASES (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.